We are live on ! Find out more

Drug Manufacturers - General
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
LLY icon
1
Eli Lilly
LLY
$1.12T
$1.12T $1,255.40 0.88%
JNJ icon
2
Johnson & Johnson
JNJ
$651B
$651B $270.24 1.07%
ABBV icon
3
AbbVie
ABBV
$468B
$468B $264.96 1.2%
MRK icon
4
Merck
MRK
$376B
$376B $152.55 2.39%
NVS icon
5
Novartis
NVS
$302B
$302B $158.86 1.68%
AZN icon
6
AstraZeneca
AZN
$257B
$257B $165.98 0.91%
AMGN icon
7
Amgen
AMGN
$238B
$238B $439.33 1.29%
NVO
8
Novo Nordisk
NVO
$207B
$207B $46.74 1.3%
GILD icon
9
Gilead Sciences
GILD
$181B
$181B $146.12 1.87%
PFE icon
10
Pfizer
PFE
$160B
$160B $28.07 1.01%
BMY icon
11
Bristol-Myers Squibb
BMY
$137B
$137B $67.01 2.35%
SNY icon
12
Sanofi
SNY
$110B
$110B $45.85 1.55%
GSK icon
13
GSK
GSK
$105B
$105B $52.41 0.87%
BIIB icon
14
Biogen
BIIB
$32B
$32B $216.78 1.13%
GRFS
15
Grifois
GRFS
$5.44B
$5.44B $8 0.13%
OGN icon
16
Organon & Co
OGN
$3.61B
$3.61B $13.75 0.07%
AMRN
17
Amarin Corp
AMRN
$298M
$298M $14.09 0.21%
LCTX icon
18
Lineage Cell Therapeutics
LCTX
$273M
$273M $1.08 0%
PLX icon
19
Protalix BioTherapeutics
PLX
$192M
$192M $2.38 0%
ARMP icon
20
Armata Pharmaceuticals
ARMP
$190M
$190M $5.10 15.4%
PTHS
21
Pelthos Therapeutics
PTHS
$97.7M
$97.7M $25.51 4.31%
MAIA icon
22
MAIA Biotechnology
MAIA
$84.5M
$84.5M $1.39 0.72%
OSTX
23
OS Therapies Inc
OSTX
$73.3M
$73.3M $1.59 0.63%
SER icon
24
Serina Therapeutics
SER
$72.9M
$72.9M $2.87 8.3%
SDEV
25
Stablecoin Development Corp
SDEV
$57.7M
$57.7M $1.14 1.79%
1
2

Drug Manufacturers - General Stocks at a Glance

Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.

There are 48 Drug Manufacturers - General industry stocks tracked by Wall St. Rank, worth a combined $4.35T.

The largest by market cap are Eli Lilly (LLY) at $1.12T, Johnson & Johnson (JNJ) at $651B and AbbVie (ABBV) at $468B.

Among institutional investors, Eli Lilly (LLY) drew the most net new fund positions in Q2 2026: 411 funds opened new positions, taking total fund holders up 229 (5.2%) quarter-over-quarter.

  • Combined market cap: $4.35T across 48 stocks.
  • Largest constituent: Eli Lilly (LLY), $1.12T market cap.
  • Most net new fund positions in Q2 2026: Eli Lilly (LLY), +229 holders.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.